Could Johnson & Johnson Be a Millionaire-Maker Stock?
Investors looking for low volatility and steady, reliable returns have been attracted to Johnson & Johnson (NYSE: JNJ) for decades. The company is a Dividend King, having raised its payout for 58 consecutive years. It's the model of a diversified healthcare company with $82 billion in annual sales, spread across consumer products, medical devices, and pharmaceuticals.
That size comes with benefits and drawbacks. While no one business unit can drag the company down, it's hard for management to keep the top line growing when its sales volume is already so high. In the last decade, the company has only averaged 3% revenue growth per year. Despite that, there are a few products that investors are hoping will reignite sales and cause Johnson & Johnson's stock to outperform the overall market for the next few years.
Image source: Getty Images.
Source Fool.com
